47
Participants
Start Date
August 10, 2019
Primary Completion Date
January 9, 2024
Study Completion Date
January 9, 2024
ICP-022
ICP-022 at a dose of 150mg PO QD
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei
West China hospital of sichuan university, Sichuan
Union Hospital affiliated to Fujian Medical University, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
First Affiliated Hospital of Zhengzhou University, Zhengzhou
Henan Cancer Hospital, Zhengzhou
Henan Provincial Peoples's Hospital, Zhengzhou
Tongji Hospital affiliated to Huazhong University of Science and Technology, Wuhan
Jiangsu Province Hospital, Nanjing
The First Affiliated Hospital of Soochow University, Suzhou
Shengjing Hospital of China Medical University, Shenyang
Ruijin Hospital affiliated to Shanghai Jiao Tong University, Shanghai
Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin
Union Hospital affiliated to Huazhong University of Science and Technology, Hubei
The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY